2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.17 Odintsov

PP01.17 Odintsov - Abstract

Pdf Summary

This study examines lung squamous cell carcinoma (LUSC) cases with targetable genetic changes, which are often less studied compared to lung adenocarcinoma. The research identified 45 out of 503 LUSC cases (8.9%) with mitogenic driver alterations such as KRAS, MET, EGFR, ERBB2, ALK, and ROS1. Majority of these alterations (68.9%) are targetable with FDA-approved therapies for non-small cell lung cancer (NSCLC). Notably, MET alterations were more common in LUSC compared to LUAD. Patients with KRAS mutations were mostly smokers, while those with MET alterations had a higher proportion of never or light smokers. Some patients with MET exon 14 skipping alterations received MET tyrosine kinase inhibitors with varying responses. The study emphasizes the importance of tumor next-generation sequencing (NGS) in expanding treatment options for LUSC patients. Despite guidelines suggesting sequencing for never or light smokers, it was found that a significant number of cases with targetable alterations occurred in moderate or heavy smokers. This research sheds light on the clinicopathologic and genomic characteristics of LUSC, highlighting the potential for personalized treatment based on genetic profiles in this less-studied subtype of lung cancer.

Keywords

lung squamous cell carcinoma

genetic changes

driver alterations

KRAS

MET

EGFR

FDA-approved therapies

tyrosine kinase inhibitors

tumor next-generation sequencing

personalized treatment